the aid library

LIST OPTIONS

Filter

6491

Sort by:

Direction:

Download (21)

View PDF (23)

2023 GINA Main Report, Global Strategy for Asthma Management and Prevention

Global Institute for Asthma (2023) CC2

The 2023 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one o... more

Download (28)

View PDF (22)

Publication: Gendered Impacts of the COVID-19 Crisis in Uganda and Opportunities for an Inclusive and Sustainable Recovery

Alys, W.; Aziz, A.; Caran Ann, M. (2022) CC2

As Uganda builds back from the COVID-19 shock, the Ugandan government is strengthening its commitment to a more gender-inclusive and sustainable economy. This report supports these efforts by describing the gendered impacts of COVID-19 and provides recommendations for Ugandan policy makers and World... more

Download (28)

View PDF (22)

Kenya Asthma Management Guideline

Ministry of Health (2021) CC

Bonchial asthma is the most common chronic respiratory disease in the world. In Kenya, it has been estimated that about 7.5% of the Kenyan population, nearly 4 million people, are currently living with asthma. Many cases tend to be underdiagnosed and undertreated which leads to high levels of morbid... more

Download (27)

View PDF (23)

Global Strategy for Asthma Management and Prevention (2023 update)

Global Initiative for Asthma (2023) CC2

Asthma is a serious global health problem affecting all age groups. Its prevalence is increasing in many countries, espacially among children. Although some countries have seen a decline in hospitalizations and deaths from asthma, asthma still imposes an unacceptable burden on health care systems, a... more

Download (42)

View PDF (67)

The Global Asthma Report 2022

Global Asthma Network (2022) CC2

The Global Asthma Report (GAR) 2022, prepared by the Global Asthma Network (GAN), is the fourth such report (others 2011, 2014, 2018). GAN builds upon the work of the International Study of Asthma and Allergies in Childhood (ISAAC) and The International Union Against Tuberculosis and Lung Disease (T... more

Download (25)

View PDF (90)

Global Strategy for Asthma Management and Prevention (2022 update)

Global Initiative for Asthma (2022) CC2

The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessi... more

Download (27)

View PDF (123)

Global Strategy for Asthma Management and Prevention (2019 update)

Global Initiative for Asthma (2019) CC2

Download (24)

View PDF (85)

Proposed Strategies to Improve Adult Asthma Management in Egypt: Expert Review and Recommendations

Hosny, H.; Madkour, A.; Hantera, M.; et al. (2022) CC2

Several challenges face asthma management in Egypt, including the high percentage of uncontrolled patients, inadequate compliance, and overuse of short-acting beta-agonists (SABAs) leading to increased asthma-related morbidity and mortality. In this regard, the recent Global Initiative for Asthma (G... more

Download (37)

View PDF (83)

2020 Brazilian Thoracic Association recommendations for the management of asthma

Menezes Pizzichini, M. M.; de Carvalho-Pinto, R. M.; Delfini Cançado, J. E.; et al. (2020) CC2

The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... more

Download (152)

View PDF (104)

Global Malaria Programme operational strategy 2024–2030
recommended

World Health Organization WHO (2024) C_WHO

Ahead of World Malaria Day, the WHO Global Malaria Programme published a new operational strategy outlining its priorities and key activities up to 2030 to help change the trajectory of malaria trends, with a view to achieving the global malaria targets. The strategy outlines 4 strategic objectives ... more

Download (114)

View PDF (336)

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t... more

Download (121)

View PDF (111)

Financing for Sustainable Development Report 2021

Inter-agency Task Force on Financing for Development United Nations (UN) (2021) CC

The 2021 Financing for Sustainable Development Report responds to the request made by Member States to review the impact of the COVID-19 pandemic on nancing for sustainable development, and to propose recommendations to rebuild better. The report underlines the need for policy actions to ensure e e... more

Download (131)

View PDF (82)

Agenda item 6: CRP1: Joint United Nations Programme on HIV/AIDS- Resource Mobilization Strategy (2022-2026)

UNAIDS (2022) CC

UNAIDS leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. It unites the efforts of 11 UN Cosponsor organizations- UNHCR, UNICEF, WFP, UNDP,UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank- and a Secretari... more

Download (108)

View PDF (89)

Results Report - Programme budget 2020–2021 - Executive Summary

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

This results report for the biennium 2020–2021 presents the progress towards the triple billion targets, outcomes and outputs, based on the GPW 13 results framework and indicators. It uses structured methodologies, both quantitative and qualitative, for measuring and analysing the achievements and... more

Download (138)

View PDF (129)

Sick Development

Anna Marriott Oxfam International (2023) CC

Development finance institutions owned by European governments and the World Bank Group are spending hundreds of millions of dollars on expensive for-profit hospitals in the Global South that block patients from getting care, or bankrupt them, with some even imprisoning patients who cannot afford th... more

Download (106)

View PDF (106)

G2H2 Report on Financial Justice for Pandemic Prevention, Preparedness and Response

Geneva Global Health Hub (2022) CC

A year ago, the second Special Session of the World Health Assembly (WHASS) unanimously agreed to start a diplomatic process for a new binding instrument aimed at ensuring the international community is better prepared for the next health emergencies. The establishment of an Intergovernmental Negoti... more

Download (85)

View PDF (99)

The impact of COVID-19 o development assistance

Brown S. Sage Journals (2021) CC

This article analyzes the impact of the COVID-19 pandemic on foreign aid. Using examples from Canadian foreign aid, it argues that, despite the terrible toll it is exacting, the crisis has accelerated some significant positive pre-existing trends, both by destabilizing the perception of aid as flowi... more

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (100)

View PDF (104)

Tuberculosis Research Funding Trends 2005-2020

World Health Organisation (WHO) (2021) C_WHO

Previous advocacy efforts have achieved tangible goals in terms garnering political commitments to increase financing for TB—as seen at the 2018 UN High-Level Meeting on TB. The challenge now is to ensure that these commitments are actually met within a global biomedical research ecosystem that... more

Download (206)

View PDF (141)

A guide to tailoring health programmes: Using behavioural and cultural insights to tailor health policies, services and communications to the needs and circumstances of people and communities

World Health Organization WHO (2023) CC

WHO/Europe has launched a new guide, providing support to countries on how to apply behavioural and cultural insights (BCI) for health. It presents a simple step-wise approach, complemented by a rich collection of detailed considerations, tools and exercises. The guide is the first of its kind, spec... more

Global Malaria Programme operational strategy 2024–2030 recommended

Global Malaria Programme operational strategy 2024–2030
recommended